STOCK TITAN
  1. Home
  2. News
  3. RZLT

Rezolute Inc - RZLT STOCK NEWS

Welcome to our dedicated news page for Rezolute (Ticker: RZLT), a resource for investors and traders seeking the latest updates and insights on Rezolute.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rezolute's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rezolute's position in the market.

News
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
Rhea-AI Summary
Rezolute, Inc. (Nasdaq: RZLT) announces the presentation of sub-analyses from the Phase 2 RIZE study at the 2024 Pediatric Endocrine Society Annual Meeting. The study evaluates RZ358 in treating congenital hyperinsulinism, showing potential as a safe and effective therapy. Key findings include significant improvements in hypoglycemia events and glucose levels, indicating promise for patients with HI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.21%
Tags
clinical trial
-
News
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
Rhea-AI Summary
Rezolute, Inc. (RZLT) announces positive results from a preclinical study validating the potential of lead compound RZ358 to treat hypoglycemia in non-islet cell tumors (NICTs). The company's drug shows promise in addressing hyperinsulinism caused by various tumor types, expanding its potential patient population. Dr. Brian Roberts, Chief Medical Officer, highlights the broad utility of RZ358 in treating hypoglycemia resulting from any form of hyperinsulinism, including expanded tumor indications. Rezolute plans to initiate a single registrational study with the FDA for patients with hypoglycemia due to tumor hyperinsulinism, potentially including both ICTH and NICTH patients, which could more than double the addressable market for RZ358. Additionally, the company is conducting a Phase 3 clinical trial in congenital HI, further showcasing the drug's versatility and potential therapeutic benefits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
-
News
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
Rhea-AI Summary
Rezolute, Inc. (Nasdaq: RZLT) announces progress in Phase 3 clinical study of RZ358 for congenital hyperinsulinism and potential late-stage development for tumor-associated hyperinsulinism. Financial results for the second quarter of fiscal 2024 show $96.0 million in cash and investments, with $13.9 million net loss.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.76%
Tags
earnings
News
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
Rhea-AI Summary
Rezolute, Inc. (RZLT) appoints Daron Evans, MS, MBA, as Chief Financial Officer and grants share options as an inducement for his appointment, aiming to strengthen its leadership team in the pursuit of developing therapies for metabolic and rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.37%
Tags
management
-
News
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Rhea-AI Summary
Rezolute, Inc. (Nasdaq: RZLT) has received the Innovation Passport designation from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for their drug RZ358, intended for the treatment of hypoglycemia due to congenital hyperinsulinism (HI). This designation was granted based on the significant unmet medical need in this condition and the potential for RZ358 to benefit patients, as evidenced by the Phase 2 RIZE study. The Innovation Passport is the first step in the Innovative Licensing and Access Pathway (ILAP) and aims to accelerate the time to market and facilitate patient access to medicines. Rezolute is enthusiastic about the potential to bring this therapy to patients in need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.08%
Tags
none
-
News
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
Rhea-AI Summary
Rezolute, Inc. (Nasdaq: RZLT) has initiated sunRIZE, a pivotal Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism (cHI), with enrollment expected to be completed by the end of 2024 and topline results reported in mid-year 2025. The Phase 3 study follows the successful Phase 2 trial, demonstrating promising results in treating cHI. The company has received a priority medicines (PRIME) designation of RZ358 for the treatment of cHI from the European Medicines Agency. The study will enroll up to 56 participants and be conducted at approximately 20 expert centers in more than a dozen countries around the world.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.52%
Tags
clinical trial
News
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
Rhea-AI Summary
Rezolute, Inc. (Nasdaq: RZLT) completes enrollment in RZ402 Phase 2 study for diabetic macular edema, expects to report topline data in mid-second quarter 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
clinical trial
-
News
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"
Rhea-AI Summary
Stonegate Healthcare Partners (Ticker: RZLT) presents 'Black Friday Biotech Sale: 12 Stocks for XBI-MAS' report, highlighting a unique opportunity in the biotech sector. The report showcases a carefully curated shopping list of top 1% publicly traded biotech companies with institutional support, robust pipelines, upcoming milestones, and strong management teams. Key takeaways include the significant decline in biotech stocks, with the XBI biotech index 56% lower than its 5-year high, and 30% of NASDAQ-listed biotech companies trading at negative enterprise value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
none
-
News
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
Rhea-AI Summary
Rezolute, Inc. (Nasdaq: RZLT) to participate in BTIG’s 3rd Annual Ophthalmology Day, discussing RZ402, an oral plasma kallikrein inhibitor for diabetic macular edema. Investor meetings to be held on November 27th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
conferences
News
Rezolute Reports First Quarter Fiscal 2024 Results
Rhea-AI Summary
Rezolute, Inc. (Nasdaq: RZLT) announced its financial results for the first quarter of fiscal 2024, showing a total of $106.9 million in cash, cash equivalents, and investments in marketable debt securities. The company is on track to commence its Phase 3 study for RZ358 to treat congenital hyperinsulinism and has obtained PRIME eligibility from the European Medicines Agency for this indication. They also anticipate completing enrollment this quarter for their ongoing Phase 2 study of RZ402 for the treatment of diabetic macular edema.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.39%
Tags
earnings
Stock RZLT logo
Rezolute Inc

Nasdaq:RZLT

RZLT Rankings

#4216 Ranked by Market Cap
#4405 Ranked by Stock Gains
N/A Ranked by Dividends

RZLT Stock Data

106.99M
22.39M
20.45%
77.72%
0.64%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Redwood City

About RZLT

rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases. rezolute is advancing a diversified pipeline including: rz358 (phase 2), an antibody for the ultra-orphan indication of congenital hyperinsulinism (chi) with an abbreviated path-to-market strategy; ab101 (phase 1), a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management by reducing the therapeutic burden for patients and improving compliance; and rz402 (plan to file ind in h2 2018), a plasma kallikrein inhibitor (pki) targeting diabetic macular edema (dme). for more information, visit: www.rezolutebio.com.